Year: 2013
Type: article
Abstract: Ivacaftor, an oral potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, has been shown to be efficacious in patients heterozygous for the G551D mutation in CFTR. This letter describes the effect of ivacaftor in a patient homozygous for this mutation.
Source: New England Journal of Medicine
DOI: 10.1056/nejmc1213681
Authors: Michael J. Harrison, Desmond M. Murphy, Barry J. Plant
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2321608101
